ERBB2 and neoplasm: In another study conducted by de Langen et al. to assess the effect of trastuzumab and paclitaxel treatment in patients who were EGFR positive and had progression with the use of EGFR-TKI along with Her2 overexpression (IHC 1 + to 3 + or Her2 gene copy number > 1), they reported that about 46% out of the enrolled 24 patients showed an objective tumor response which was notably higher in those harboring Her2 score 3 + by IHC [54].